Autonomix Medical Inc SEC Filings

Autonomix Medical, Inc. discloses executive pay actions and a proposed reverse stock split. New CEO Brad Hauser joined on June 17, 2024 with an annual base salary of $450,000. Several executives—Mr. Schwartz, Mr. Toth and Mr. Klemp—took voluntary pay reductions that include one-time and ongoing cuts, resulting in each of Mr. Schwartz, Mr. Toth and Mr. Klemp having an annual salary of $50,000 on a go-forward basis. The statement also describes option vesting schedules that vest over four years in annual installments for grants referenced on July 24, 2023 and June 21, 2024. The Reverse Stock Split provision states outstanding common shares will be combined and converted into one share without changing par value or authorized share counts, that fractional shares will be cashed out based on the five-day Nasdaq closing price average, and that authorized shares are 500,000,000 common and 10,000,000 preferred.

Autonomix Medical, Inc. amended its at-the-market equity program by increasing the aggregate sales price available under its At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc. On August 25, 2025 the company increased the original capacity of $2.1 million by an additional $1.4 million, and any sales will be made under the company’s effective Form S-3 registration statement (File No. 333-285464) and related prospectus supplement filed August 25, 2025. The filing references the February 28, 2025 sales agreement and legal opinions from ArentFox Schiff LLP.

Autonomix Medical, Inc. (AMIX) entered into a purchase agreement with Lincoln Park Capital Fund, LLC on August 25, 2025, under which Lincoln Park committed to purchase up to $15.0 million of the company’s common stock over a period of up to 24 months, subject to a Commencement Date that requires an effective registration statement and satisfaction of other conditions. The company issued 261,932 commitment shares to Lincoln Park as consideration. Daily purchases (Regular Purchases) are limited by share-count and a per-transaction dollar cap of $500,000, with purchase price formulas tied to recent trading prices and additional mechanics for accelerated purchases. Limits include a Nasdaq 19.99% exchange cap (unless shareholder approval is obtained or average price conditions are met) and a 4.99% beneficial ownership cap for Lincoln Park. Proceeds are expected to be used for working capital and general corporate purposes.

Autonomix Medical, Inc. is a pre-revenue, clinical-stage life sciences company focused on technologies for sensing and treating peripheral nervous system disorders. The company reported no revenue for the years ended March 31, 2025 and 2024 and an accumulated deficit of approximately $50.4 million with working capital of about $7.9 million as of March 31, 2025; management states there is substantial doubt about the company’s ability to continue as a going concern within one year. The company completed a financing in November 2024 that raised gross proceeds of approximately $10.0 million (net cash proceeds ~$9.0 million) via Common Units and Pre-Funded Units with attached Series A Warrants and Representative’s Warrants. Subsequent liquidity actions include an ATM program (small sales reported: 800 shares for ~$1,746 as of March 31, 2025 and 1,304,260 shares for net proceeds of ~$2.1 million as of June 30, 2025). As of June 30, 2025 the company reported $8.6 million cash, working capital of $7.0 million, and an accumulated deficit of $53.7 million. The filings disclose extensive warrant activity, equity-classified offering warrants, potential reverse stock split authority, and stock-based compensation plans.

Autonomix Medical, Inc. received an amended Schedule 13G disclosing that BioStar Ventures III entities beneficially own 175,216 shares of common stock, representing 4.3% of the outstanding common stock on a fully adjusted basis. BioStar Ventures III, L.P. directly holds 120,816 shares and warrants exercisable for 54,400 shares; BioStar Ventures III, L.L.C. is the general partner and shares voting and dispositive power over the same 175,216 shares. The filing states the ownership calculation is based on 4,022,625 shares outstanding adjusted to include shares issuable upon exercise of the warrants. The Reporting Persons disclaim being a group and indicate this position constitutes 5% or less of the class.

Amendment to Schedule 13G for Autonomix Medical, Inc. (AMIX) filed by a group of investment entities and individuals discloses that the listed Reporting Persons—Cavalry Fund I LP; C/M Capital Master Fund, LP; C/M Capital Partners, LP; Mercer Street Global Opportunity Fund, LLC; Mercer Street Capital Partners, LLC; Thomas Walsh; and Jonathan Juchno—report zero shares beneficially owned of Autonomix common stock (CUSIP 05330T205), representing 0% of the class. The filing identifies relationships among the entities: C/M Capital Partners is manager to the Cavalry and C/M Master funds, Mercer Capital Partners manages the Mercer fund, and Messrs. Walsh and Juchno are managing members or control persons for the relevant managers. The business address for the Reporting Persons is 61 82 E. Allendale Rd. Ste 5B, Saddle River, NJ 07458. The signatories certify the securities were not acquired to influence control of the issuer.

Brad Hauser, identified as an officer (CEO and President) of Autonomix Medical, Inc. (AMIX), reported a transaction with an earliest transaction date of 08/11/2025.

The filing discloses a derivative option that represented the right to buy 45,000 shares of common stock with an exercise price of $27, exercisable beginning 06/17/2025 and expiring 06/17/2034. The option was cancelled by mutual agreement, and the reporting person received three months' severance as consideration. The Form 4 is signed by an attorney-in-fact on behalf of Brad Hauser dated 08/13/2025.